Studies how polycystic ovary syndrome looks different from person to person
Observes women aged 18 to 49 with polycystic ovary syndrome in Alsace, France.
Plain-language title generated from the registry record
Registry title: Phenotyping of Patients With Polycystic Ovary Syndrome
Key facts
- Where
- Strasbourg, FranceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women who saw a doctor at Strasbourg University Hospitals for suspected polycystic ovary syndrome (PCOS), or whose PCOS was found during care for another hormone problem.
- Age
- 18 years to under 50 years (the registry lists 18 to 49 years)
- Sex
- The registry lists all sexes, but the criteria say adult women.
- Disease stage
- Suspected or discovered polycystic ovary syndrome (PCOS).
Main reasons for not taking part
- Final diagnosis that rules out PCOS
Read by machine on 13 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 49 years old?
Source: NCT07339930, who can take part
Where in France
- ervice d'Endocrinologie, Diabétologie et Nutrition - CHU de Strasbourg - FranceStrasbourg, FranceContact: Thibault BAHOUGNE, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT07339930
- Record updated
- 14 January 2026
- Original description
Polycystic ovary syndrome (PCOS) is the leading endocrine disorder of the reproductive system, affecting 10 to 13% of women of childbearing age. However, there is a significant delay in diagnosis, which may be due to considerable clinical heterogeneity and a lack of information among the general population. The diagnosis is made when two of the three Rotterdam criteria established in 2003 and revised in 2023 are met, namely: 1) menstrual cycle disorders (oligoanovulation) - 2) clinical or biological hyperandrogenism - 3) OPK morphological appearance or elevated anti-Müllerian hormone (AMH) levels, after exclusion of differential diagnoses. PCOS is a condition that carries a risk of metabolic complications and fertility problems due to dysovulation. Patients have an impaired quality of life and are at greater risk of anxiety and depression, which should be screened for systematically.Read full original descriptionShow less
Phenotyping of Patients With Polycystic Ovary Syndrome (PCOS) in Alsace, France
Polycystic ovary syndrome (PCOS) is the leading endocrine disorder of the reproductive system, affecting 10 to 13% of women of childbearing age. However, there is a significant delay in diagnosis, which may be due to considerable clinical heterogeneity and a lack of information among the general population. The diagnosis is made when two of the three Rotterdam criteria established in 2003 and revised in 2023 are met, namely: 1) menstrual cycle disorders (oligoanovulation) - 2) clinical or biological hyperandrogenism - 3) OPK morphological appearance or elevated anti-Müllerian hormone (AMH) levels, after exclusion of differential diagnoses. PCOS is a condition that carries a risk of metabolic complications and fertility problems due to dysovulation. Patients have an impaired quality of life and are at greater risk of anxiety and depression, which should be screened for systematically.
Inclusion: Adult woman (≥18 years and <50 years); Subject who consulted at the Strasbourg University Hospitals for suspected PCOS or for any other endocrinological condition that led to the discovery of PCOS.
Exclusion: Final diagnosis excluding PCOS.